Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study

Background: Fingolimod was the first oral therapy approved for treating relapsing-remitting multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy of fingolideR, 0.5 mg in Iranian MS patients during one-year follow-up. Methods: A multicenter, open-label, longitudi...

詳細記述

書誌詳細

主要な著者:	Rozita Doosti, Abdorreza Naser Moghadasi, Amir Reza Azimi, Shahrokh Karbalai Saleh, Masoud Etemadifar, Vahid Shaygannejad, Fereshteh Ashtari, Mohammad Hossein Harirchian, Bahaadin Siroos, Hormoz Ayramloo, Nastaran Majdinasab, Seyyed Mohammad Masood Hojjati, Nabiollah Asghari, Seyed Mohammad Baghbanian, Hamed Cheraghmakani, Mahmoud Abedini, Behnaz Sedighi, Negar Mohseni Abbas abadi, Maedeh Ghasemitabar, Sara Talebianpour, Tohid Babayi Daylari, Vahid Dana, Neda Ghaleh noie, Mohammad Ali Sahraian
フォーマット:	Artigo
言語:	Inglês
出版事項:	Babol University of Medical Sciences 2021-04-01
シリーズ:	Caspian Journal of Internal Medicine
主題:	fingolimod multiple sclerosis safety edss
オンライン･アクセス:	http://caspjim.com/article-1-2280-en.html
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!